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Abstract
Background: Human Barrett’s cancer cell lines have numerous, poorly-characterized genetic abnormalities and,
consequently, those lines have limited utility as models for studying the early molecular events in carcinogenesis. Cell
lines with well-defined genetic lesions that recapitulate various stages of neoplastic progression in Barrett’s esophagus
would be most useful for such studies.
Methodology/Principal Findings: To develop such model cell lines, we started with telomerase-immortalized, non-
neoplastic Barrett’s epithelial (BAR-T) cells, which are spontaneously deficient in p16, and proceeded to knock down p53
using RNAi, to activate Ras by introducing oncogenic H-Ras
G12V, or both. BAR-T cells infected with either p53 RNAi or
oncogenic H-Ras
G12V alone maintained cell-to-cell contact inhibition and did not exhibit anchorage-independent growth in
soft agar. In contrast, the combination of p53 RNAi knockdown with expression of oncogenic H-Ras
G12V transformed the
p16-deficient BAR-T cells, as evidenced by their loss of contact inhibition, by their formation of colonies in soft agar, and by
their generation of tumors in immunodeficient mice.
Conclusions/Significance: Through these experiments, we have generated a number of transformed and non-transformed
cell lines with well-characterized genetic abnormalities recapitulating various stages of carcinogenesis in Barrett’s
esophagus. These lines should be useful models for the study of carcinogenesis in Barrett’s esophagus, and for testing the
efficacy of chemopreventive and chemotherapeutic agents.
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Introduction
The incidence of esophageal adenocarcinoma, a lethal tumor
that develops from the metaplastic epithelium of Barrett’s
esophagus, has increased profoundly in the United States over
the past several decades [1,2]. Knowledge of the molecular events
underlying carcinogenesis in Barrett’s metaplasia might facilitate
the development of effective preventive and treatment strategies
for esophageal adenocarcinoma. Unfortunately, the molecular
mechanisms underlying the malignant transformation of Barrett’s
esophagus remain unclear.
Studies on the early molecular events in Barrett’s carcinogenesis
have been hampered by the lack of appropriate model systems. For
example, the results of studies using animal models of Barrett’s
esophagus, which have involved rats primarily, may not be
applicable to humans because of the substantial inter-species
differences in esophageal physiology and tissue structure. Human
Barrett’s cancer cells have sustained numerous, poorly character-
ized genetic injuries and, therefore, cell lines derived from those
malignanciesareoflimited valueforstudyingearlymolecularevents
in carcinogenesis. Biopsy specimens of Barrett’s epithelium can be
cultured ex vivo, but such explants have a short lifespan and cannot
be used to study long-term carcinogenetic effects. A durable, in vitro
model that starts with non-malignant, human, Barrett’s metaplastic
cells to recapitulate the various stages of neoplastic progression
might be most useful for studying the early molecular mechanisms
underlying malignancy in Barrett’s esophagus.
In 2000, Hanahan and Weinberg characterized six physiologic
hallmarks of cancer that normal cells acquire to become malignant
[3]. These hallmarks include the ability of cells to provide their
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e13093own growth signals, to avoid growth inhibitory signals, to resist
apoptosis, to replicate without limit, to synthesize new blood
vessels, and to invade and metastasize [3]. Recent studies have
shown that normal cells can acquire these hallmarks through
disruptions in surprisingly few key growth regulatory pathways
such as the retinoblastoma (Rb) and p53 pathways, the mitogenic
signaling pathways (including Ras), and the telomerase-dependent
replicative senescence pathway [4].
We have developed cultures of human Barrett’s epithelial cells
from esophageal biopsy specimens of non-neoplastic Barrett’s
metaplasia, and we have immortalized those cells by forcing them
to express telomerase. These non-neoplastic cell lines demonstrate
spontaneous loss of p16 expression [5]. By introducing additional,
well-defined genetic alterations that target the p53 and Ras
pathways, we have induced the malignant transformation of our
telomerase-immortalized human Barrett’s epithelial cells, and we
have developed a number of non-transformed cell lines with well-
defined, growth-promoting genetic changes that might recapitu-
late various stages of neoplastic progression in Barrett’s esophagus.
Results
p53 knockdown alone does not induce malignant
transformation of Barrett’s epithelial cells
The population of BAR-T cells infected with pSuper-p53RNAi
exhibited a marked decrease in baseline p53 expression, with a
selected clone showing complete elimination of baseline p53
expression (Figure 1A). In response to UV-B irradiation, a well-
known inducer of p53 and p21, there was an increase in p53 and
p21 expression in the control and vector-only cells. UV-B evoked a
smaller increase in p53 and p21 expression in the p53-knockdown
cell population, with the selected clone showing virtually no
increase in p53 and p21 expression.
We next determined the population doubling time in BAR-T
p53RNAi cells. Normally, functional p53 increases population
doubling time and, therefore, we expected our p53 knockdown
cells to exhibit decreased doubling times. However, we found no
such decrease in doubling time in our p53 knockdown cell
population. Indeed, we noted a small, but statistically significant
increase in population doubling time in the selected clone
(Figure 1B). The explanation for this unanticipated effect is not
clear, and further studies are warranted to explore this issue.
Cell to cell contact does not inhibit growth in transformed cells.
To seek evidence of malignant transformation in our p53-
knockdown BAR-T cells, therefore, we assessed cell to cell contact
inhibition. After 8–10 days in culture, vector control and pSuper-
p53RNAi knockdown cells (population & clone) all demonstrated a
plateau in cell growth characteristic of intact contact inhibition
(Figure 1C), suggesting that Barrett’s cells with knockdown of p53
are not transformed. As an additional test for in vitro transforma-
tion, we cultured our p53 knockdown cells in soft agar to see if they
exhibited anchorage-independent growth. As a positive control,
we used a lung cancer cell line (SEG1), which makes numerous
colonies after 3 weeks in soft agar (data not shown). Neither our
vector-only nor p53-knockdown BAR-T cells (population & clone)
formed colonies in soft agar (data not shown). These findings
Figure 1. p53 knockdown in BAR-T cells. (A) Western blot demonstrating expression of p53 and p21 at baseline and after irradiation with 200 J/
m
2 UV-B in controls, vector-only cells, the entire p53 RNAi-containing population and a p53 RNAi-containing clone with nearly complete p53
knockdown; b-actin served as a loading control. (B) Population doubling time in BAR-T cells containing p53 RNAi. (*, p,0.05 compared to vector
control) (C) Cell-to-cell contact inhibition in BAR-T cells containing p53 RNAi. Cell numbers increase significantly in a time-dependent manner up to
day 8 in vector-only cells (p,0.001) and in the p53-knockdown population (p,0.001), and up to day 10 in the clone (p,0.05).
doi:10.1371/journal.pone.0013093.g001
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transformation of Barrett’s epithelial cells.
Overexpression of oncogenic H-Ras
G12V alone does not
induce malignant transformation of Barrett’s epithelial
cells
We infected BAR-T cells with pBabe-H-Ras
G12V, and deter-
mined the expression of H-Ras and the phosphorylation of its
downstream proteins (MEK and ERK) in two H-Ras-infected
clones (R6 and R7) and in a clone that contained only the vector.
We were unable to generate a complete population of oncogenic
H-Ras
G12V-containing cells (despite numerous attempts) because,
each time we performed selection for BAR-T infected with pBabe-
H-Ras
G12V, only isolated colonies would survive. As shown in
Figure 2A, BAR-T cells infected with H-Ras
G12V showed a
marked increase in H-Ras expression associated with an increase
in phosphorylation of MEK1/2 and ERK1/2, indicating that the
H-Ras
G12V was functionally active.
We next determined population doubling time and cell to cell
contact inhibition in BAR-T cells expressing H-Ras
G12V.I nf u l l
medium containing serum and supplemental growth factors, we
found no significant differences in doubling times between our H-
Ras
G12V-expressing clones and the vector control (Figure 2B). As
expected, the H-Ras
G12V-expressing cells showed a growth advan-
tage over vector controls when grown in reduced medium (0.5% of
the concentration of serum and growth factors found in full media),
further supporting that the H-Ras
G12V was functionally active (data
not shown). Both our vector control and H-Ras
G12V-expressing cells
demonstrated a plateau in cell growth after 5–7 days in culture,
indicating that they maintain contact inhibition (Figure 2C). In
addition, the cells did not form colonies in soft agar, demonstrating
that oncogenic H-Ras
G12V does not induce anchorage-independent
growth in BAR-T cells (data not shown). These findings suggest that
expressionofoncogenicH-Ras
G12Valonedoesnotinduce malignant
transformation of Barrett’s epithelial cells.
p53 knockdown combined with overexpression of
oncogenic H-Ras
G12V induces malignant transformation
of Barrett’s epithelial cells
Having found that neither p53 knockdown alone nor expression
ofoncogenicH-Ras
G12Valoneinducedmalignanttransformationof
our BAR-T cells, we next combined these genetic alterations. We
used our BAR-T p53RNAi-expressing clone for infection with
oncogenic H-Ras
G12V. We then selected one vector-only containing
clone and two additional H-Ras
G12V-expressing clones (R1 and R2)
for further characterization. There was a marked increased in
expression of H-Ras, phospho-MEK1/2 and phospho-ERK1/2 in
BAR-T p53RNAi cells infected with H-Ras
G12V (Figure 3A). The
clones with combined H-Ras
G12V expression and p53 knockdown
exhibited a significant decrease in population doubling time
(Figure 3B), and a loss of cell to cell contact inhibition (Figure 3C).
After 3 weeks of culture in soft agar, we observed several colonies of
our BAR-T p53RNAi H-Ras
G12V-expressing clones, whereas the
vector control cells did not form colonies (Figure 4). To determine
whether the BAR-T p53RNAi H-Ras
G12V-expressing clones have
the cancer cell abilities of migration and invasion,we used the BAR-
T p53RNAi H-Ras
G12V clone R1 cells for migration and invasion
assays. Compared to BAR-T control cells, transformed BAR-T
Figure 2. H-Ras
G12Vexpression in BAR-T cells. (A) Western blots demonstrating H-Ras expression as well as phosphorylation of two downstream
proteins (MEK1/2 and ERK1/2) in a clone containing vector only, and in two H-Ras
G12V-infected clones(R6 and R7); b-tubulin served as a loading
control. (B) Population doubling time in BAR-T cells containing H-Ras
G12V. (C) Cell–to-cell contact inhibition in BAR-T cells containing H-Ras
G12V. Cell
numbers increased significantly in a time-dependent manner up to day 5 in a clone containing vector only (p,0.05) and up to day 7 in two H-
Ras
G12V-infected clones (R6 and R7; p,0.05).
doi:10.1371/journal.pone.0013093.g002
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G12VR1 cells demonstrated a significant increase in
cell migration and invasion (Figure 5 A and B). These data suggest
that oncogenic H-Ras
G12V in combination with p53 knockdown
induces neoplastic transformation of Barrett’s epithelial cells.
The ‘‘gold standard’’ assay to define tumorigenicity is the ability
of cells to form tumors in immunodeficient mice. Therefore, we
injected BAR-T p53RNAi H-Ras
G12V-expressing clones (R1 and
R2) subcutaneously into Nu/Nu mice (T cell deficient) and NOD/
SCID mice (T, B, and NK cell deficient as well as complement
deficient). SEG-1 cells served as a control for the Nu/Nu mice;
OE33 cells served as a control for the NOD/SCID mice. Unlike the
vector-containing control cells (BAR-T p53RNAi cells containing
the empty vector p-Babe-zeocin), the cells with p53 knockdown and
H-Ras
G12V expression formed tumors in both the Nu/Nu (Table 1)
and the NOD/SCID mice within 10–14 weeks (Table 1 and
Figure 6A). There were no significant differences between the
average volumes of the in vivo tumors formed by the OE33 cancer
cells and those formed by BAR-T p53 RNAi cells expressing H-
Ras
G12V clones R1 and R2 (Figure 6B). Histological evaluation of
the tumors revealed mucin-containing glands typical of an
adenocarcinoma (Figure 6C). To confirm that the xenograft tumors
maintained p53 knockdown and overexpression of oncogenic H-
Ras
G12V, Western blots for p53 and H-Ras were performed
on tissue from 4 individual xenograft tumors derived from the
BAR-T p53RNAi+H-Ras
G12VR1 cells. Similar to the BAR-T
p53RNAi+H-Ras
G12V R1 cells in vitro, the xenograft tumor tissues
derived from these cells lacked p53 expression and had elevated
levels of H-Ras expression (Figure 7). These data demonstrate that
the molecular changes introduced into the BAR-T cells in vitro (p53
knockdown and overexpression of oncogenic H-Ras
G12V) were
maintained by the cells that generated the tumors in vivo.
To confirm that p53 knockdown and overexpression of
oncogenic H-Ras
G12V induce malignant transformation of Bar-
rett’s epithelial cells, we infected a second telomerase-immortal-
ized Barrett’s epithelial cell line (BAR10-T) with pSuper-p53RNAi
followed by infection of the population of p53RNAi-expressing
cells (rather than a selected clone) with pBabe- H-Ras
G12V.
Following selection with zeocin, we selected a resultant p53RNAi
H-Ras
G12V-expressing clone (R5) for characterization of in vivo
tumorigenesis. These cells produced tumors in both the Nu/Nu
and the NOD/SCID mice within 6 weeks (Table 1). Histological
analysis showed that the tumors consisted of moderately to poorly
differentiated carcinoma with areas of both squamous and
glandular differentiation. Portions of the tumor also exhibited
goblet cells, poorly differentiated sarcomatoid features, and
necrosis (data not shown).
Transformed Barrett’s cells have clonal chromosomal
abnormalities
Conventional cytogenetic analysis identified complex clonal
chromosome aberrations in all three transformed cell lines. Our
analysis of 20 metaphase cells for each tumor revealed for
the BAR-T p53RNAi H-Ras
G12V-expressing clone R1 a 46,53,
XY,+X,add(1)(p12),+5,+6,+9,214,+15,add(15)(q24),+19,+20,+21,
Figure 3. H-Ras
G12Vexpression in BAR-T p53 RNAi knockdown cells. (A) Representative western blot demonstrating H-Ras expression as well
as phosphorylation of MEK1/2 and ERK1/2 in a clone containing vector only, and in two H-Ras
G12V-infected, p53 knockdown clones (R1 and R2); b-
tubulin served as a loading control. (B) Population doubling time in a clone containing vector only, and in two H-Ras
G12V-infected, p53 knockdown
clones (R1 and R2). (*, p,0.05 compared to vector control) (C) BAR-T p53 RNAi cells expressing H-Ras
G12V demonstrate loss of cell-to-cell contact
inhibition. In contrast to a clone containing vector only in which cell numbers level off after day 10, cell numbers in the two H-Ras
G12V-infected, p53
knockdown clones (R1 and R2) continued to increase significantly in a time-dependent manner (p,0.001 for clones R1 and R2).
doi:10.1371/journal.pone.0013093.g003
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del(8)(p11.2p23),+9,del(12)(q15q24.3),add(13)(q32), i(13)(q10),
214,+19,+20,+1,4mar[cp3]/83,89,XXY,-Y,add(1)(p12),
del(1)(q12), 22,del(2)(q11.2), 24,+5,+6,der(7)t(7;13)(q11.2;q12),
add(8)(p11.2),del(8)(p11.2p23),+9, 211, 212,del(12)(q15q24.3),
213,add(13)(q32),i(13)(q10), 214,der(14)t(14;22)(p11.2;q11.2),
215,add(15)(q24), 216, 218, add(18)(q11.2), 219,+20, 221,
add(21)(q22), 222,+2,7mar[14] karyotype (Figure 8A); for
the BAR-T p53RNAi H-Ras
G12V-expressing clone R2 a
55,79,2n.,XY,+X,add(1)(p12),+2,+3,+4,+5,+5,+5,+6,+6,+7,
del(8)(p11.2p23),+9,+9,+10,+10,+11,+12,add(13)(q32),i(13)(q10),
der(14)t(14;22)(p11.2;q11.2),add(15)(q24),+16,+17,+19,+20,
+20,+21, 222[cp7]/81,89,4n.,XXY,-Y, 21,add(1)(p12), 22,
24,+5,+6, 27,del(8)(p11.2p23),+9, 210, 211, 212,add(13)(q32),
i(13)(q10),add(15)(q24), 216, 217, 218, 218,+20, 221, 222,
222[cp13] karyotype (Figure 8B); and for the BAR-10T
p53RNAi H-Ras
G12V-expressing cells a 91,XXYY,4n.,23,+5,
+8, 29, 213, 214, 221,+2mar[20] karyotype. Thus the Barrett’s
cells transformed in vitro displayed clonal chromosomal abnormal-
ities consistent with neoplasia.
Discussion
We have shown that malignant transformation of benign Barrett’s
epithelial cells can be achieved invitro through disruption of relatively
few key growth regulatory pathways including the p16/Rb and p53
checkpoint arrest pathways, the mitogenic Ras signaling pathway,
and the telomerase-dependent replicative senescence pathway. As a
result of these experiments, we have established a series of
transformed and non-transformed Barrett’s epithelial cell lines that
can be used to elucidate the contribution of specific genetic
alterations, alone and in combination, to carcinogenesis in Barrett’s
esophagus. Moreover, our series of Barrett’s epithelial cell lines with
well-defined genetic alterations can be used to explore the molecular
mechanisms by which environmental factors (e.g. acid and bile
exposure) promote cancer development in Barrett’s esophagus, and
totesttheefficacyofchemopreventiveandchemotherapeuticagents.
The molecular alterations that have been proposed to
contribute to carcinogenesis in Barrett’s esophagus can be patchy
in distribution and heterogeneous in nature [6]. Consequently, the
identification of those molecular abnormalities can be heavily
influenced by biopsy sampling error. This problem confounds
attempts to determine the precise order in which genetic
alterations accumulate. Nevertheless, available studies using biopsy
specimens from patients with Barrett’s esophagus support a
carcinogenetic role for alterations in the same pathways that
caused transformation of our non-neoplastic Barrett’s epithelial
cells in vitro, i.e. the p16/Rb and p53 checkpoint arrest pathways,
the mitogenic Ras signaling pathway, and the telomerase-
dependent replicative senescence pathway.
Figure 4. A. Anchorage-independent growth in soft agar of BAR-T p53 RNAi cells expressing H-Ras
G12V. No colonies are observed for the vector-
containing control cells, whereas a number of colonies are observed (circled) for the BAR-T p53 RNAi cells expressing H-Ras
G12V (clones R1 and R2).
Selected colonies for clones R1 and R2 are shown at higher magnification (4X). B. Quantification of colonies for the vector-containing control cells and for
theBAR-Tp53 RNAicellsexpressingH-Ras
G12V(clonesR1andR2).The SEG1cancercells formed 325.3614.4SEM colonies andservedas a positivecontrol.
doi:10.1371/journal.pone.0013093.g004
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the neoplastic transformation of human cells [7]. A number of
normal cell types (including esophageal squamous cells) have been
immortalized through the forced expression of telomerase alone or
in combination with the insertion of viral oncoproteins such as the
SV40-early region [8,9]. Viral oncoproteins can cause a
substantial number of poorly characterized genetic alterations
[10], however, a feature that limits the utility of those cells for
studies on the contribution of specific genetic alterations. Cells
immortalized with human telomerase have shown no signs of
tumorigenesis, altered differentiation, or deregulation of cell
proliferation [11]. Moreover, expression of telomerase RNA has
been detected in tissue samples of non-dysplastic, Barrett’s
metaplasia suggesting that telomerase activation is an early event
in Barrett’s carcinogenesis [12,13]. Thus, we selected to bypass the
replicative senescence pathway by immortalizing our Barrett’s
epithelial cells (BAR-T and BAR10-T) solely through the
introduction of human telomerase (hTERT).
Functional disruption of the Rb pathway can be achieved by
inactivation of p16, which is the earliest and most common genetic
alteration described in patients with Barrett’s esophagus [14].
Biopsy specimens of non-neoplastic Barrett’s metaplasia demon-
strate inactivation of p16 via promoter methylation, loss of
heterozygosity (LOH), or mutation in 73% to 87% of patients
[15,16]. Therefore, it is not surprising that both our BAR-T and
BAR10-T cell lines exhibit spontaneous loss of p16 expression.
Figure 5. A. Migration of BAR-T p53 RNAi cells expressing H-Ras
G12V clone R1 cells. Visualization by the fluorescent dye calcein AM of cells that have
migrated through the membrane; quantification of cell migration for BAR-T p53 RNAi cells expressing H-Ras
G12V clones R1 and BAR-T control cells. (B)
Invasion of BAR-T p53 RNAi cells expressing H-Ras
G12V clone R1 cells. Visualization by the fluorescent dye calcein AM of the cells that have invaded
through the membrane; quantification of cell invasion for BAR-T p53 RNAi cells expressing H-Ras
G12V clones R1 and BAR-T control cells. Bar graphs
depict the mean + SEM. (*, p,0.0001 compared to control).
doi:10.1371/journal.pone.0013093.g005
Table 1. H-Ras
G12V-Expressing BAR-T p53RNAi Cells Are Tumorigenic In Vivo.
Cell Line
Tumors/Injections NOD/SCID Mice
(QT, B, NK cells, Qcomplement) Tumors/Injections Nude Mice (QT cells)
BAR-T p53 RNAi +Vector 0/4 (26 weeks) 0/4 (26 weeks)
BAR-T p53 RNAi + HRasG
12VR1 4/4 (10 weeks) 3/4 (10 weeks)
BAR-T p53 RNAi + HRasG
12VR2 3/4 (12 weeks) 3/4 (14 weeks)
BAR10-T p53 RNAi + HRasG
12VR5 6/6 (6 weeks) 3/4 (6 weeks)
doi:10.1371/journal.pone.0013093.t001
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the effects of well-defined genetic alterations on neoplastic
transformation would be one in which p16 expression remains
intact, with the deficiency in p16 expression being genetically
engineered, rather than spontaneously acquired. Spontaneous loss
of p16 expression does not negate our attempts at establishing an
in vitro model of neoplastic progression in Barrett’s esophagus
however, as p16 inactivation is an early genetic event in
metaplastic Barrett’s epithelial cells in vivo [14,16]. Our BAR-T
and BAR10-T cell lines also express Barrett’s epithelial cell
differentiation markers such as villin and cytokeratins 4, 8, and 18,
and both lines exhibit contact inhibition and anchorage-dependent
growth. Thus, our telomerase-immortalized, p16-deficient BAR-T
and BAR10-T cell lines are not transformed and appear to be a
good model for non-neoplastic Barrett’s metaplasia.
In an attempt to transform our non-neoplastic Barrett’s
epithelial cells, we knocked down the p53 pathway using a specific
p53RNAi expression vector. This was done to recapitulate the p53
allelic loss that appears to occur frequently during carcinogenesis
in Barrett’s esophagus. In biopsy specimens of non-dysplastic
Barrett’s metaplasia, allelic loss of p53 occurs more frequently than
p53 mutation and, in the absence of p53 allelic loss, p53 mutations
are rare [16,17]. Loss of p53 is found frequently in biopsy
specimens of Barrett’s esophagus that also exhibit p16 inactivation,
and the limited data available on the order in which these genetic
alterations accumulate suggest that loss of p53 follows the
inactivation of p16 [16]. In our BAR-T cells, which are already
p16 deficient, specific knockdown of the p53 pathway alone did
not induce features of neoplastic transformation. This finding is
consistent with reports on other human epithelial cells (including
esophageal squamous, embryonic kidney, and mammary cells) in
which the introduction of telomerase in combination with the
SV40 early region (a viral oncoprotein that knocks down the Rb
and p53 pathways) results in immortalized, but not transformed
cells [9,10,18].
We also activated the mitogenic Ras signaling pathway in our
non-neoplastic Barrett’s cells by introducing an expression vector
containing oncogenic H-Ras
G12V. Involvement of the Ras
pathway in the early stages of neoplastic progression in Barrett’s
esophagus has been suggested by studies demonstrating genomic
amplification or overexpression of the epidermal growth factor
receptor (EGFR) and its ligand, transforming growth factor alpha
(TGF-a), in biopsy samples of non-dysplastic Barrett’s metaplasia
[19,20]. Although specific K-Ras mutations and expression of
oncogenic H-Ras are rarely detected in non-neoplastic Barrett’s
epithelium, both of these abnormalities are found frequently in
dysplastic Barrett’s epithelium and in esophageal adenocarcino-
mas [21–25].
In some primary epithelial cells, activation of oncogenic Ras
causes oncogene-induced senescence, a form of growth arrest that
appears to prevent cancer formation [26]. In telomerase-
immortalized esophageal squamous epithelial cells, H-Ras
G12V-
induced senescence has been shown to be mediated via the
upregulation of p16 [27]. Thus, it is not surprising that our BAR-T
cells, which are p16 deficient, did not exhibit growth arrest after
the introduction of H-Ras
G12V. Indeed, population doubling times
Figure 6. In vivo tumor formation by BAR-T p53 RNAi cells expressing H-Ras
G12V. (A) Three representative tumors formed by BAR-T p53
RNAi cells expressing H-Ras
G12V clone R1 in the NOD/SCID mouse model. (B) There were no significant differences between the average volumes of
the in vivo tumors formed by the OE33 cancer cells and those formed by BAR-T p53 RNAi cells expressing H-Ras
G12V clones R1 and R2 (p=.88). (C)
Histology of the tumors demonstrating mucin-containing glands (circled) typical of an adenocarcinoma.
doi:10.1371/journal.pone.0013093.g006
Barrett’s Cell Transformation
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e13093for those cells did not differ significantly from those of vector-
containing control cells. The oncogenic H-Ras
G12V produced by
our Barrett’s cells was functional, as evidenced by an associated
increase in the levels of phosphorylation of the downstream
proteins MEK1/2 and ERK1/2. Nevertheless, oncogenic Ras
expression alone did not transform our BAR-T cells. Similar
findings have been reported for a telomerase-immortalized human
fibroblast cell line in which the combination of p16 downregula-
tion and expression of oncogenic H-Ras
G12V did not induce
neoplastic transformation [28].
A number of primary human epithelial cells, including
esophageal squamous cells, have been transformed using a
combination of viral oncoproteins, hTERT, and oncogenic Ras
[9,18,29,30]. Few reports have documented the transformation of
human epithelial cells in the absence of viral oncoproteins [31].
Without using viral oncoproteins, we have achieved transforma-
tion of telomerase-immortalized, non-neoplastic, human Barrett’s
epithelial cells, which are deficient in p16, by introducing a
combination of p53 knockdown and oncogenic H-Ras
G12V
expression. When the transformed cells were injected into
immunodeficient mice, the resulting tumors demonstrate histolog-
ical phenotypes similar to those of Barrett’s-associated esophageal
adenocarcinomas. We also found that the transformed Barrett’s
cells had clonal chromosomal abnormalities consistent with
malignancy. It is possible that the chromosomal abnormalities
associated with the knockdown of p53 and the insertion of
oncogenic H-Ras
G12V contributed to malignant transformation.
In conclusion, without using viral oncoproteins, we have
induced the malignant transformation of human hTERT-
immortalized Barrett’s epithelial cells, which are deficient in
p16, through the knockdown of p53 and the forced expression of
oncogenic H-Ras
G12V. Similar genetic alterations are found
frequently in esophageal biopsy specimens from patients with
various stages of neoplasia in Barrett’s esophagus. Through these
experiments, we have generated a number of transformed and
non-transformed human Barrett’s epithelial cell lines with well-
characterized genetic abnormalities that can be used as models for
the study of carcinogenesis in Barrett’s esophagus, and for testing
the efficacy of chemopreventive and chemotherapeutic agents.
Materials and Methods
Ethics Statement
Experimental methods using mice were approved by the
Institutional Animal Care and Use Committee at the Dallas VA
Medical Center under ACORP #05-049.
Cell culture
We used 2 non-neoplastic, telomerase-immortalized Barrett’s
epithelial cell lines (BAR-T and BAR10-T) that were established in
our laboratory from endoscopic biopsy specimens of non-
dysplastic Barrett’s specialized intestinal metaplasia taken from
two patients with long-segment Barrett’s esophagus [5,32]. Like
BAR-T cells [5], our BAR10-T cells express Barrett’s epithelial
cell differentiation markers such as villin and cytokeratins 4, 8, and
18, develop spontaneous loss of 16 protein expression, demon-
strate cell to cell contact inhibition, and do not exhibit anchorage-
independent growth in soft agar (data not shown). Conventional
cytogenetic analysis identified a 47, XY, +5[7]/90–93,4n.,
XXYY,-8[cp5]/46,XY[18] karyotype in BAR10-T cells. BAR cell
lines were co-cultured with a fibroblast feeder layer and
maintained in supplemented keratinocyte basal media, KBM2,
(Lonza, Walkersville, MD) as previously described [5,33]. Cells
were equally seeded into collagen IV-coated wells (BD Biosciences,
Figure 7. Western blots demonstrating expression of p53 and H-Ras in BAR-T cells, two H-Ras
G12V-infected clones (R6 and R7), p53
RNAi-containing clone, BAR-T p53 RNAi cells expressing H-Ras
G12V (clone R1), and tissue from 4 xenograft tumors (Tumor 1–4)
derived from BAR-T p53 RNAi cells expressing H-Ras
G12V (clone R1). Note that tissue samples from all 4 xenograft tumors demonstrate
knockdown of p53 and expression of H-Ras. b-tubulin served as a loading control; MCF7 cells served as a positive control for p53 expression.
doi:10.1371/journal.pone.0013093.g007
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specified, we used the BAR-T line for most experiments because
of the extensive characterization of this line done by our
laboratory [5,32,34–36].
Viral vectors and vector transduction
For knockdown of p53, we generated pSUPER-RNAi-p53 by
cloning the DNA fragment containing the p53 RNAi sequence
from the pSUPER.p53 plasmid (OligoEngine, Seattle, WA) into
the EcoR1/HindIII cloning site of the pSUPER.retro.neo
retroviral mammalian expression vector (OligoEngine) as previ-
ously described [34]. The pBabe-puromycin-based retroviral
vector expressing human oncogenic H-Ras
G12V and pBabe-zeocin
were obtained from Dr. Robert Weinberg (Whitehead Institute,
Cambridge, MA)[30]. The DNA fragment containing oncogenic
H-Ras
G12V was digested (EcoR1/BamH1, Roche, Indianapolis,
IN) from pBabe-puromycin and cloned into the EcoR1/BamH1
cloning site of the pBabe-zeocin retroviral mammalian expression
vector generating the retroviral vector pBabe- H-Ras
G12V –zeocin;
pBabe-zeocin without the insert served as a control. pBabe- H-
Ras
G12V –zeocin was transformed into competent bacterial cells
(Subcloning Efficiencey DH5a, Invitrogen) per the manufacturer’s
instructions. Ampicillin-resistant colonies were selected, plasmid
was isolated, and the presence of the insert was confirmed by
EcoRI and BamH1 digestion and DNA sequencing. Retroviral
particles were generated as previously described [8]. BAR-T and
BAR10-T cells were infected at approximately 50% confluence in
the presence of 4 mg/ml of Polybrene (Sigma, St. Louis, MO) for
10–12 hours. After recovery for 72 hours, cells were selected in
60 mg/ml G418 or 80 mg/ml zeocin for 10 days. Cell clones were
selected using cloning cylinders. We generated BAR-T cells
containing 1) pSUPER-retro.neo (vector control); 2) pSUPER-
p53RNAi; 3) pBabe-zeocin (vector control); 4) pBabe- H-Ras
G12V
–zeocin; 5) pSUPER-p53RNAi and pBabe-zeocin; and 6)
pSUPER-p53RNAi and pBabe- H-Ras
G12V –zeocin.
UV-B irradiation
UV-B irradiation was performed as previously described [34].
Cells were irradiated with 200 J/m
2 of UV-B and 24 hours later,
cells were collected for Western blot analysis.
Western blotting
Cells were lysed in 1X cell lysis buffer (Cell Signaling
Technology, Beverly, MA); protein concentrations were deter-
Figure 8. Representative karyotype of BAR-T p53 RNAi + H-Ras
G12V cells prior to their use in the in vivo tumorigenesis assays (A)
clone R1 and (B) clone R2. Structural aberrations are designated with an arrow.
doi:10.1371/journal.pone.0013093.g008
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Equal amounts of protein were separated by SDS-polyacrylamide
gel electrophoresis and transferred to nitrocellulose membranes.
The membranes were incubated with primary antibodies (1:1,000
dilutions) to p53, H-Ras, phospho- and total MEK1/2, and
phospho- and total ERK1/2 or (1:500 dilutions) p21 (Cell
Signaling Technology). Horseradish peroxidase secondary anti-
bodies were used and chemiluminescence was determined using
the Super Signal West Dura detection system (Pierce, Rockford,
IL); b-actin or b-tubulin (Sigma) was used to confirm equal
loading. All Western blots were performed in duplicate.
Growth rate and population doubling time
Cell numbers were determined using a Z1 particle counter
(Beckman Coulter, Fullerton, CA). Population doublings and
doubling times were determined using the formulas PD=log (Nt/
N0)/log (2) and DT (hours) = (t–t0)/PD where t0=time at which
the cells were seeded, t=time in hours, Nt=cell number at time t,
and N0=initial cell number seeded, respectively. All experiments
were performed in duplicate.
Cell to cell contact inhibition
Cell to cell contact inhibition was performed as previously
described [5]. In brief, 83610
3 cells per well of a 6 well plate were
seeded and placed in the incubator for at least10 days. Cell counts
were performed using a Z1 particle counter at various time points.
All experiments were performed in duplicate.
Soft agar assay
The soft agar assay was performed as previously described [5].
In brief, 1000 cells were added to 2.5 ml of Noble agar (Sigma)
which had been kept at 45uC (final concentration of 0.33% (w/v)
agar) and supplemented with 20% serum. The cell-agar mixture
was plated in duplicate onto dishes containing a solidified.5 ml
layer of 0.5% agar-cell culture medium mix. Cells were fed
weekly with growth media and plates were examined daily for 3
weeks. Plates were imaged with a Bio-Rad Molecular Imager
(Bio-Rad, Hercules, CA, USA). SEG-1 lung adenocarcinoma cells
were used as a positive control. All experiments were performed in
duplicate.
Migration and invasion Assays
For both migration and invasion assays, cells were equally
seeded onto a BD Falcon FluoroBlok 24-Multiwell Insert plate
with an 8.0 m pore size; for the invasion assay the plate was coated
with BD Matrigel Matrix (BD Biosciences, Bedford, MA). For
both assays, KBM-2 growth media was placed in the bottom of the
wells as a chemoattractant. After 3 hours, the cells on the bottom
of the filters were labeled with the fluorescent dye calcein AM
(4 mg/ml). Images were obtained from 2 separate high power fields
from three individual wells and cells were counted to determine
the proportion which migrated or invaded through the membrane.
Cytogenetic analysis
Cytogenetic analysis was performed on BAR-T p53 RNAi H-
Ras
G12V-expressing clones R1 and R2, and BAR-10T p53 RNAi
H-Ras
G12V-expressing clone R5 cells prior to their use in the in vivo
tumorigenesis assays. Dividing cells were harvested from cultures
incubated without mitogen, and Trypsin G-banded using standard
methods [37]. Briefly, metaphase BAR-T p53 RNAi H-Ras
G12V-
expressing clones R1 and R2, and BAR-10T p53 RNAi H-
Ras
G12V-expressing clone R5 cells were obtained by colcemid
arrest followed by hypotonic treatment with pre-warmed 0.075M
KCl. They were then fixed and washed in freshly made modified
Carnoy’s fixative (3:1 absolute methanol:glacial acetic acid),
dropped onto pre-cleaned, wet microscope slides and air-dried.
Cytogenetic abnormalities were classified according to the
International System for Human Cytogenetic Nomenclature [38].
In vivo tumorigenesis
Female 6 week old, specific pathogen free, nude mice (nu/nu)
and NOD/SCID mice were obtained (Charles River Labs,
Wilmington, MA) and allowed to acclimate to the animal facilities
at the Dallas VA Medical Center for one week. 5–1610
7 cells were
suspended in 250 ml of growth media and then mixed with 250 ml
(total volume of 500 ml) of Matrigel (BD Biosciences, Franklin
Lakes, NJ) and implanted under the skin of the mouse in the dorsal
flank; SEG-1 lung adenocarcinoma cells or OE33 esophageal
adenocarcinoma cells were used as a positive control. Mice were
assessed daily for tumor formation and growth. At sacrifice,
tumors were removed and processed by fixing in 4% formalde-
hyde solution followed by immersion in 10% neutral buffered
formalin, dehydration, and paraffin embedding. Five micron
paraffin-embedded sections were stained with hematoxylin and
eosin (H&E) for histologic assessment. Calipers were used to
measure the tumor length and width. The volume of each tumor
was determined using the modified ellipsoidal formula Volume=
K (length X width
2); the resulting tumor volumes were then
averaged.
Statistical Analyses
Quantitative data are expressed as the mean + the standard
error of the mean (SEM). Statistical analysis was performed using
ANOVA and the Student-Newman-Keuls multiple-comparison
test with the Instat for Windows statistical software package
(GraphPad Software, San Diego, CA). P values ,0.05 were
considered significant for all analyses.
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